Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ANTHOTCMKTS:PXYNOTCMKTS:SNNAQOTCMKTS:SPHSOTCMKTS:STLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANTHAnthera Pharmaceuticals$0.00$0.00▼$0.00N/A1.8210 shs10 shsPXYNPraxsyn$0.00$0.00▼$0.00N/AN/AN/AN/ASNNAQSienna Biopharmaceuticals$0.00$0.00▼$0.00N/A0.31N/AN/ASPHSSophiris Bio$0.00$0.00▼$0.05$4K1.94N/AN/ASTLTSpotlight Innovation$0.00$0.00▼$0.04N/AN/AN/A100 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANTHAnthera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PXYNPraxsyn0.00%0.00%0.00%0.00%0.00%SNNAQSienna Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%SPHSSophiris Bio0.00%0.00%0.00%0.00%0.00%STLTSpotlight Innovation0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/AN/AN/AN/ASNNAQSienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANTHAnthera Pharmaceuticals 0.00N/AN/AN/APXYNPraxsyn 0.00N/AN/AN/ASNNAQSienna Biopharmaceuticals 0.00N/AN/AN/ASPHSSophiris Bio 0.00N/AN/AN/ASTLTSpotlight Innovation 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/AN/ASNNAQSienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANTHAnthera PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/APXYNPraxsynN/AN/A0.00N/AN/AN/AN/AN/AN/ASNNAQSienna BiopharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/A0.00N/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/ASNNAQSienna BiopharmaceuticalsN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANTHAnthera PharmaceuticalsN/APXYNPraxsynN/ASNNAQSienna BiopharmaceuticalsN/ASPHSSophiris BioN/ASTLTSpotlight InnovationN/AInsider OwnershipCompanyInsider OwnershipANTHAnthera Pharmaceuticals2.08%PXYNPraxsynN/ASNNAQSienna Biopharmaceuticals27.20%SPHSSophiris Bio4.50%STLTSpotlight InnovationN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANTHAnthera Pharmaceuticals20N/AN/ANot OptionablePXYNPraxsyn66N/AN/ANot OptionableSNNAQSienna Biopharmaceuticals60N/AN/ANot OptionableSPHSSophiris Bio635.55 millionN/ANot OptionableSTLTSpotlight Innovation4N/AN/ANot OptionablePXYN, STLT, SNNAQ, SPHS, and ANTH HeadlinesRecent News About These CompaniesThe Silver Screen Spotlight: “Jurassic World: Rebirth”July 5 at 11:36 AM | weau.comWSunrise Spotlight: Mud Happens! Early Bird Registration Today!July 5 at 11:36 AM | wnky.comWCommunity Spotlight: First United Methodist ChurchJuly 5 at 11:36 AM | kpax.comKSpotlight on the News: Inside the Detroit mayoral race; Haashiim & PerkinsJuly 5 at 11:36 AM | wxyz.comWOutlook Business Spotlight Initiative - India's Best CEOJuly 4 at 8:19 AM | outlookindia.comSpotlight boss calls for sector unity in speech ahead of Equity court caseJuly 4 at 3:19 AM | thestage.co.ukTSpotlight Innovation (OTCMKTS:STLT) & Align Technology (NASDAQ:ALGN) Financial SurveyJuly 3 at 2:21 AM | americanbankingnews.com2025 Senior Spotlight: Newark ValleyJuly 1, 2025 | wicz.comWExclusive Cover Reveal + Q&A: Amy Spalding Concludes Her Out In Hollywood Series with In Her SpotlightJuly 1, 2025 | pastemagazine.comPSenior Spotlight – Ballston Spa’s Mia Collins leaves as a trailblazer for Section 2 girls wrestlingJuly 1, 2025 | msn.comIn The Spotlight: Here come the brides for RebeccaJuly 1, 2025 | msn.comPokemon Go Spotlight Hour Schedule July 2025July 1, 2025 | ign.comICBRE India Recognized as ‘Company of the Year’ at Outlook Business Spotlight Enterprise & Leadership Awards 2025June 30, 2025 | uniindia.comUKD Sunday Spotlight: Tunnels To TowersJune 29, 2025 | msn.comSenior Spotlight: Sherburne-EarlvilleJune 29, 2025 | wicz.comWLocal Spotlight: California's Master Plan for AgingJune 29, 2025 | abc30.comAIndie App Spotlight: ‘Coffee in the Sun’ helps you find an ideal outdoor spot to hangJune 29, 2025 | 9to5mac.com910 Ways MacBook's Spotlight Search Can Help Make Your Life A Little EasierJune 29, 2025 | msn.comSenior Spotlight: Charlotte ValleyJune 28, 2025 | wicz.comWThe Silver Screen Spotlight: “F1: The Movie”, “M3GAN 2.0″, and more!June 28, 2025 | weau.comWMedia Sentiment Over TimePXYN, STLT, SNNAQ, SPHS, and ANTH Company DescriptionsAnthera Pharmaceuticals OTCMKTS:ANTHAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Praxsyn OTCMKTS:PXYNPraxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.Sienna Biopharmaceuticals OTCMKTS:SNNAQSienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.Sophiris Bio OTCMKTS:SPHSSophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.Spotlight Innovation OTCMKTS:STLTSpotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
